LMWH in coronary artery disease: A review and future perspectives;Acquis et perspectives des héparines de bas poids moléculaire

Archives des Maladies du Coeur et des Vaisseaux

Volumn 94, Issue 11 SUPPL., 2001, Pages 1233-1242

  Collet, J Ph ^a   Choussat, R ^a   Montalescot, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOEMBOLISM;

EID: 0038645326     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Aspirin, heparin, or both to treat acute unstabe angina
2. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis
3. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
4. Low-molecular weight heparin during instability in coronary artery disease
5. FRAxiparine in ischaemic syndrome. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction FRAXIS
6. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC)
7. Comparison between low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
8. Enoxaparin prevents death and cardiac ischemic events in unstable angina / Non-Q-Wave myocardial infarction. Results of Thrombolysis In Myocardial Infarction (TIMI) 1 1 B trial
9. Assessment of the treatment of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 1 1 B-Essence meta-analysis
10. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events
11. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO trial
12. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
13. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with low molecular weight heparin and with direct thrombin inhibitor
14. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
15. ARMADA study: A randomized comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina
16. ACC/AHA guidelines for the management of patients with unstable angina and non-ST elevation myocardial infarction: Executive summary and recommendations
17. Antithrombotic agents in coronary artery disease
18. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST elevation; recommendations of the Task Force of the European Society of Cardiology
19. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of heparin and aspirin reperfusion therapy (HART II)
20. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
21. Dose-ranging trial of enoxaparin for unstable angina agents: Results of TIMI 11 A
22. Antithrombotic therapy in patients undergoing percutaneous coronary intervention
23. Defining the optimal activated clottinq time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials
24. Platelets glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularzation
25. Percutaneous coronary intervention following subcutaneous enoxaparin pre-treatment in patients with unstable angina pectoris
26. Pharmacokinetic study, of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI study
27. Low molecular weight heparin (Reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)
28. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
29. Low-molecular-weight-heparin therapy in percutaneous coronary intervention: The NICE-1 and NICE-4 trials
30. Effect og glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
31. Dalteparin in combination with abciximab during percutaneous coronary intervention
32. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: TheNICE 3 story
33. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
34. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
35. Enoxaparin in unstable angina patients with renal failure
36. Long term anticoagulation of outpatients with adverse events to oral anticoagulants with low molecular weight heparin
37. Acute Massive post operative atrial thrombosis in a patient undergoing low molecular heparin anticoagulation
38. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses
39. Thrombosis in a mechanical aortic valve prosthesis during subcutaneous heparin therapy in pregnancy;a case report
40. Low molecular weight heparin after mechanical heart valve replacement
41. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin
42. Atrial fibrillation: Is there a role for low-molecular-weight heparin?
43. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study. Heparin in acute embolic stroke trial
44. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement